Objective:Interleukin-1 (IL-1) is known to be critically involved in ovarian carcinogenesis. We investigated a panel of polymorphisms of the IL-1 and the IL-1 receptor antagonist (IL-1 RA) genes in patients with ovarian cancer.
Methods:One hundred thirty-four patients with surgically staged ovarian cancer, 27 patients with borderline ovarian cancer, and 134 healthy controls were genotyped for three polymorphisms of the IL-1 gene (-889 C/T polymorphism of the IL-1alpha gene [IL1A], -511 C/T polymorphism of the IL-1beta promoter [IL1B promoter], a polymorphism of IL-1beta exon 5 [IL1B exon 5]), and an 86-base pair repeat in intron 2 of the IL-1 RA gene [IL1RN]) using polymerase chain reaction and pyrosequencing.
Results:Allelic frequencies did not differ between patients with ovarian cancer and controls. In the ovarian cancer group, polymorphism did not correlate with any of the investigated clinicopathologic variables, including tumor stage, lymph node, and histologic grade. In univariate and multivariate models, there was no correlation between any polymorphism and patients' overall and disease-free survival.
Conclusion:We investigated interleukin polymorphisms in ovarian cancer but did not find any association between common polymorphisms of IL1A, IL1B, and IL1RN and the occurrence of ovarian cancer. Allelic variation within the IL-1 gene clusters does not seem to play a role in ovarian carcinogenesis and does not appear to be a useful tool for possible screening and risk evaluation.
1. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J1994;8:1314-1325.
2.
2. Dinarello CA. Interleukin-1. Ann N Y Acad Sci1988;546:122-132.
3.
3. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol1998;16:457-499.
4.
4. Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest1991;88:1445-1451.
5.
5. Eisenberg SP, Brewer MT, Verderber E, Heimdal P, Brandhuber BJ, Thompson RC. Interleukin 1 receptor antagonist is a member of the interleukin 1 gene family: Evolution of a cytokine control mechanism. Proc Natl Acad Sci U S A1991;88:5232-5236.
6.
6. Nicklin MJ, Weith A, Duff GW. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics1994;19:382-384.
7.
7. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest1992;22:396-402.
8.
8. di Giovine FS, Takhsh E, Blakemore AL, Duff GW. Single base polymorphism at -511 in the human interleukin-1 beta gene (IL1 beta). Hum Mol Genet1992;1:450-450.
9.
9. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet1993;91:403-404.
10.
10. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol1995;99:303-310.
11.
11. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol1998;28:2598-2602.
12.
12. Licastro F, Pedrini S, Ferri C, et al. Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Ann Neurol2000;48:388-391.
13.
13. Hulkkonen J, Laippala P, Hurne M. A rare allele combination of the interleukin-1 gene complex is associated with high interleukin-1 beta plasma levels in healthy individuals. Eur Cytokine Network2000;11:251-255.
14.
14. Santtila S, Savinainen K, Hurme M. Presence of the IL-1RA allele 2 (IL1RN*2) is associated with enhanced IL-1beta production in vitro. Scand J Immunol1998;47:195-198.
15.
15. Castrilli G, Tatone D, Diodoro MG, Rosini S, Piantelli M, Musiani P. Interleukin 1alpha and interleukin 6 promote the in vitro growth of both normal and neoplastic human cervical epithelial cells. Br J Cancer1997;75:855-859.
16.
16. Apte RN, Douvdevani A, Zoller M, et al. Cytokine-induced tumor immunogenicity: Endogenous interleukin-1 alpha expressed by fibrosarcoma cells confers reduced tumorigenicity. Immunol Lett1993;39:45-52.
17.
17. Apte RN, Dvorkin T, Song X, et al. Opposing effects of IL-1 alpha and IL-1 beta on malignancy patterns. Tumor cells-associated IL-1 alpha potentiates anti-tumor immune responses and tumor regression, whereas IL-1 beta potentiates invasiveness. Adv Exp Med Biol2000;479:277-288.
18.
18. Glaccum MB, Stocking KL, Charrier K, et al. Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J Immunol1997;159:3364-3371.
19.
19. Barber MD, Powell JJ, Lynch SF, Fearon KC, Ross JA. A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. Br J Cancer2000;83:1443-1447.
20.
20. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature2000;404:398-402.
21.
21. Kopp WC, Urba WJ, Rager HC, et al. Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer. Clin Cancer Res1996;2:501-506.
22.
22. Veltri S, Smith JW 2nd. Interleukin 1 trials in cancer patients: A review of the toxicity, antitumor and hematopoietic effects. Stem Cells1996;14:164-176.
23.
23. Marth C, Zeimer AG, Herold M, et al. Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer1996;67:826-830.
24.
24. Li BY, Mohanraj D, Olson MC, et al. Human ovarian epithelial cancer cells cultures in vitro express both interleukin 1 alpha and beta genes. Cancer Res1992;52:2248-2252.
25.
25. Fujiwaki R, Hata T, Miyazaki K, Kawamura T, Inada K. Elevation of serum interleukin-1 receptor antagonist levels in women with gynaecological cancers. Br J Obstet Gynaecol1997;104:1407-1408.
26.
26. Zeisler H, Tempfer C, Joura EA, et al. Serum interleukin 1 in ovarian cancer patients. Eur J Cancer1998;34:931-933.
27.
27. Triozzi PL, Kim JA, Martin EW, Young DC, Benzies T, Villasmil PM. Phase I trial of escalating doses of interleukin-1 beta in combination with a fixed dose of interleukin-2. J Clin Oncol1995;13:482-489.
28.
28. Verschraegen CF, Kudelka AP, Termrungruanglert W, et al. Effects of interleukin-1 alpha on ovarian carcinoma in patients with recurrent disease. Eur J Cancer1996;32:1609-1611.
29.
29. McDowell TL, Symons JA, Ploski R, Forre O, Duff GW. A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism. Arthritis Rheum1995;38:221-228.
30.
30. Nyren P, Karamohamed S, Ronaghi M. Detection of single-base changes using a bioluminometric primer extension assay. Anal Biochem1997;244:367-373.
31.
31. Levy-Lahad E, Lahad A, Eisenberg S, et al. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci U S A2001;98:3232-3236.
32.
32. Levine DA, Boyd J. The androgen receptor and genetic susceptibility to ovarian cancer: Results from a case series. Cancer Res2001;61:908-911.
33.
33. Gershoni-Baruch R, Dagan E, Israeli D, Kasinetz L, Kadouri E, Friedman E. Association of the C677T polymorphism in the MTHFR gene with breast and/or ovarian cancer risk in Jewish women. Eur J Cancer2000;36:2313-2316.
34.
34. Schneider J, Pollan M, Jimenez E, et al. nm23-H1 expression defines a high-risk subpopulation of patients with early-stage epithelial ovarian carcinoma. Br J Cancer2000;82:1662-1670.
35.
35. Kilian PL, Kaffka KL, Biondi DA, et al. Antiproliferative effect of interleukin-1 on human ovarian carcinoma cell line (NIH: OVCAR-3). Cancer Res1991;51:1823-1828.
